Ask AI
ProCE Banner Activity

Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities

Podcast Episodes

Listen to this podcast with Nadia Harbeck, MD, and Francois-Clement Bidard, MD, PhD, sharing their thoughts on the role of AKT and PI3K inhibitors in patients with primary or secondary endocrine-resistant breast cancers.

Released: April 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd.

Target Audience

This activity is intended for medical oncologists and other healthcare professionals caring for patients with breast cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the rationale for using PI3K/AKT/mTOR pathway inhibitors in HR+/HER2- metastatic breast cancer, including their mechanisms of action and clinical relevance in biomarker-selected populations

  • Develop individualized treatment plans based on biomarker testing, the latest clinical data, and patient-specific factors for patients with HR+/HER2- PIK3CA-mutated mBC

  • Identify patients eligible for PI3Ki therapy through appropriate biomarker testing and assessment of clinical risk factors, including those for treatment-induced hyperglycemia

  • Apply practical, evidence-based strategies for mitigating and managing treatment-related hyperglycemia to optimize adherence and outcomes

Disclosure

Primary Author

Francois-Clement Bidard, MD, PhD: researcher: GE Healthcare, Menarini Silicon Biosystems, Merck KGaA, Merck Sharp & Dohme, Novartis, Personalis, Pfizer, Prolynx, Roche, Tempus; consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Foresight Dx, Inatherys, Lilly, Menarini Silicon Biosystems, Novartis, Pfizer.

Nadia Harbeck, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Menarini/Stemline, MSD, Novartis, Pfizer, Pierre Fabre, Roche.